CTOs on the Move

Healthmap Solutions

www.healthmapsolutions.com

 
Healthmap Solutions (Healthmap) is a NCQA-accredited industry leading kidney population health management company. Healthmap uses big data resources, integrated advanced technology, clinical expertise, and complex care management to improve the lives of people living with kidney disease. Healthmap also helps healthcare providers and payers achieve the value-based results they need. Our company is a diverse and growing organization committed to our clients, the patients we support, and our employees. We are champions for better health, for those who need us most.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Eric Peterson
Director Information Security Operations Profile
Deepak Suri
Chief Information Officer Profile
Russell Proulx
Chief Information Security Officer Profile

Funding

Healthmap Solutions raised $85M on 06/18/2019
Healthmap Solutions raised $35M on 05/02/2022

Similar Companies

St. Luke's Episcopal Health System

Saint Luke's Hospital of Kansas City is a 582-bed tertiary care hospital offering many specialized programs and services, with a network of 550 physicians practicing in more than 56 medical specialties.

Advanced Bionics Corporation

Advanced Bionics Corporation is a global leader in developing the most reliable, best performing cochlear implant devices in the world.

MMI

MMI is a Crystal Springs, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NMotion Physical Therapy

NMotion Physical Therapy is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Telesta Therapeutics

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.